



CONSEGNA
DELIVERING INNOVATION

Options Rights Issue – Acceptances and Shortfall Notification

22 May 2013, Melbourne: Consegna Group Limited (**Consegna or the Company**) refers to its non-renounceable pro rata options rights issue, which closed on 17 May 2013 (**Rights Issue or the Offer**).

Consegna is pleased to announce that the Company has received applications for 32,433,765 new options at an issue price \$0.004 per option raising \$129,735. The resulting shortfall from the Rights Issue is 62,966,235 options.

The Company has notified the underwriter, Peloton Capital, of the shortfall in acceptances for the options. The 62,966,235 options from the shortfall will be applied for by the underwriter (or sub-underwriters nominated by the underwriter) raising a further \$251,865.

The Board of Consegna takes this opportunity to thank all shareholders who participated in the Rights Issue for their continued support of the Company.

Media Enquiries

Michael Johnson
CEO & Executive Director
+61 (03) 9614 3663
mjohnson@consegna.com
twitter @michaelconsegna
www.consegna.com



About Consegna Group Limited (ASX:CGP)

Consegna Group Limited is a Melbourne based medical technology firm with a focus on nasal, respiratory management and drug delivery technologies.

Consegna is commercializing the BreatheAssist™ technology portfolio; an intra-nasal technology designed for the global consumer and medical health markets. The BreatheAssist technology features a device capable of dilating the nostrils and/or providing a platform for a range of bioactive ingredients. The company will be commercialising the technology in multiple applications targeting:

Consumer Markets

Sport + Exercise Performance
Snoring Management

Clinical Programs

Olfactory/Weight Management
Sleep Apnea
Drug Delivery